Peripheral Neuropathic Pain Following Breast Cancer: Effectiveness and Tolerability of High-Concentration Capsaicin Patch

Denis Dupoiron1, Sabrina Jubier-Hamon1, Valerie Seegers2, Florent Bienfait1, Yves Marie Pluchon3, Nathalie Lebrec1, Virginie Jaoul1, Thierry Delorme1

1Département Anesthésie – Douleur, Institut de Cancérologie de l’Ouest, Angers, France; 2Département de biométrie, Institut de Cancérologie de l’Ouest, Angers, France; 3Centre d’étude et de traitement de la douleur (CETD), Centre hospitalier départemental Vendée, La Roche-sur-Yon, France

Correspondence: Denis Dupoiron, Département Anesthésie – Douleur, Institut de Cancérologie de l’Ouest, Angers, France, Tel +33 2 41 35 28 73, Email denis.dupoiron@ico.unicancer.fr

Purpose: Data supporting the use of high-concentration capsaicin patches (HCCPs) in breast cancer (BC) patients and BC survivors (BCSs) with peripheral neuropathic pain (PNP) are limited. This observational study evaluated the effectiveness and safety of HCCP applications in BCSs/BC patients with PNP.

Patients and Methods: Data from all patients treated with HCCP in the pain department of a French comprehensive cancer centre were collected from 01-Jan-2014 to 14-Oct-2020. Independent pain specialists completed the Clinical Global Impression of Change (CGIC) for each included patient based on data extracted from patient’s electronic medical record compiled by the treating pain specialist after each HCCP application.

Results: Patients (N=279; mean age: 59.2 years; previous history of PNP medication: 54.5%) received on average 4.1 repeated HCCP applications (1141 HCCP applications); 68.8% received HCCP as an add-on to systemic therapy and 27.9% as first-line therapy. PNP was most frequently caused by surgery (62.4%) followed by chemotherapy (11.8%) and radiotherapy (6.5%). A complete or important analgesic effect was reported at least once by 82.3% of patients. A 6.0% reported no effect at all. For post-surgical PNP existing for <12 months and >10 years an important or complete effect was observed for 70.7% and 56.0% of applications. For chemotherapy- or radiotherapy-induced PNP, this important or complete effect was observed for 52.7% and 52.3% of applications, respectively. HCCP application was associated with site reactions in 54.4% of patients (mainly burning sensation or pain, 45.9%, or erythema, 30.8%) and high blood pressure in 7.2%.

Conclusion: This real-world chart review provides important effectiveness and safety information to clinicians when considering topical options to treat PNP in BCSs/BC patients.

Keywords: breast cancer, capsaicin, chronic pain, effectiveness, peripheral neuropathic pain, safety, topical administration

Introduction
In 2020, breast cancer (BC) became the most diagnosed cancer, with 2.3 million new cases (11.7% of all new cancer cases). Worldwide, with 685,000 deaths, it was the fifth leading cause of cancer mortality.1 Advances in treatment, early diagnosis, and mammography screening programmes have decreased its mortality.2 Although improved survival represents progress, it also means that increased numbers of patients live with the consequences of BC or its treatment. According to a systematic review, the prevalence of pain during cancer treatment is 55%,3 and according to several studies, 41% to 74% of breast cancer survivors (BCSs) suffer from chronic pain.4–8

BCSs/BC patients often experience a mixture of nociceptive pain and neuropathic pain of local and/or central origin, consistent with pain origin that is often multifactorial, and linked to the underlying cancer condition itself and its multimodal treatment, and possible comorbid conditions.9,10 However, neuropathic pain is the most reported pain type (60%), isolated or combined with other types.7,10
When present, neuropathic pain is usually chronic, persisting continuously or manifesting as recurrent episodes, and causing major suffering and disability. Recognizing the presence of neuropathic pain is important to inform pain management as it is more complex and difficult to treat than the nociceptive type and requires specific treatments targeting neuropathic mechanisms. Moreover, early pain management is paramount to decrease the probability of central pain sensitisation.

Current approaches are pharmaceutical (including antidepressants, anticonvulsants, opioids, topical treatments) and non-pharmaceutical. Unfortunately, the results of most treatment approaches, even if combined, are inconsistent and, on average, provide pain relief to less than half of the patients treated. Moreover, oral pharmaceutical treatments tend to have multiple side effects and contraindications, and do not treat the cause of the pain. BCSs/BC patients usually prefer topical treatment to avoid the adverse events associated with oral pharmaceutical treatments, especially when combined with cancer treatments such as aromatase inhibitors.

High-concentration (179 mg) capsaicin patches (HCCPs) offer an alternative local approach to oral treatments of peripheral neuropathic pain (PNP). Its efficacy is comparable to that of oral centrally acting agents but with the advantages of causing limited systemic side effects and addressing polypharmacy issues. Having shown this comparable effect and improved tolerability, recent guidelines have included HCCPs as a second-line option to treat PNP. However, published studies supporting its use in PNP in oncology are limited to small open-label studies. Against this background, after years of capsaicin use in our hospital, we aimed to evaluate the effectiveness of the patches in PNP in cancer patients. This real-world study evaluating the effectiveness and safety of this topical treatment option under usual practice conditions in a large sample of BCSs/BC patients with PNP provides important information to clinicians considering treatment options for these patients.

Materials and Methods

Study Design and Included Patients
This was a monocentric real-world data study. It took place at the Anaesthesiology and Pain department of the comprehensive cancer centre, Institut de cancérologie de l’Ouest (ICO) in Angers, France. The Anaesthesiology and Pain department was experienced in the use of HCCPs (4-year experience at the start of the study in 2018). In this centre, HCCP was commonly used for the treatment of PNP as (i) first-line monotherapy without any systemic neuropathic treatment, (ii) add-on therapy to previous neuropathic systemic pain treatment, or (iii) add-on therapy to stop or reduce systematic treatment.

The study was observational. All patients with BC treated with HCCP for PNP at the study centre were included in the study, provided that their electronic medical file included detailed information on their treatment and follow-up. Patients could be BCSs or still receiving cancer therapy; they could be male or female and could have non-cancer-associated or cancer-associated pain. Their cancer-associated neuropathic pain could be due to chemotherapy, surgery, and/or radiotherapy or the evolution of the disease.

The study was initiated on 18-Dec-2018. It retrospectively included all patients who had been treated with HCCP at the study centre since 01-Jan-2014. Data were retrospectively obtained from 01-Jan-2014 to 18-Dec-2018. For patients continuing to receive HCCP treatment as of 18-Dec-2018, ongoing prospective data collection took place until the cut-off date of 14-Oct-2020 (last visit of the last patient).

Study Treatment
HCCP was administered at the discretion of the pain specialist responsible for the care of the patient in the outpatient unit at the study centre (treating physician). The treating physician identified the area to be treated with the patch, the number of patches to be used and the number of applications as well as the time interval between applications when applicable.

Collected and Analysed Data
Each patient at the study centre has a unique electronic medical record. This file contains information on all consultations, treatments, prescriptions, and laboratory reports since the introduction of the electronic medical record in 2014. Per
standard operating procedure, the treating physicians or their designated representatives complete this file at every patient visit.

In line with the study protocol, data were extracted from the electronic medical record of all included patients and transferred to the study database. This database contained: sociodemographic and medical data, and data on pain characteristics (aetiology, duration, location, intensity before and after treatment), HCCP treatment modalities (see above), previous and concomitant treatments, and potentially HCCP-related adverse events (AEs).

**Primary and Secondary Objectives**
The main objective of this study was to assess the analgesic effect of HCCP applications in a BCS/BC patient. This analgesic effect was assessed by at least one pain specialist, who was not responsible for the patient care at the study centre. The assessment was done by completing The Clinical Global Impression of Change (CGIC)\textsuperscript{20,21} based on information from the treating physician in the patients’ electronic medical file including Numerical Rating Scale (NRS), in which patients evaluate their pain intensity from 0 (no pain) to 100 (worst pain ever possible) and/or Verbal Rating Scale (VRS) in which adjectives are used to describe different levels of pain in five points: 0: “no pain,” 1: “light pain,” 2: “moderate pain,” 3: “severe pain,” and 4: “unbearable pain”. Eight pain specialists, reviewed the extracted data as this review took several months. Most medical files were evaluated by two pain specialists. In case of divergency in the evaluation of the analgesic effect between the two pain specialists, the most unfavourable evaluation was retained.

The analgesic effect was assessed after each application as compared to status before application according to the seven categories of the CGIC: (1) No effect; (2) Clinically observable effect without pain relief; (3) Minimal effect; (4) Mild effect; (5) Moderate effect; (6) Important effect; (7) Complete effect. Detailed information is provided in Table 1.

The primary evaluation criterion was the CGIC response per application. Other criteria were the maximum CGIC response per patient throughout the treatment period and the effect of pain aetiology (chemotherapy, radiotherapy, or surgery), pain duration, and position on treatment line (first, second, or third line) on CGIC response per application.

The safety profile of HCCP treatment in BCSs/BC patients was assessed by recording local and systemic AEs and local pain severity following each application as recorded in the electronic medical file of each patient.

**Sample Size and Statistical Analysis**
No statistical sample size calculation was performed for this study as it aimed to describe the overall cohort of BCs treated with HCCP for PNP at the study centre.

A descriptive analysis was done with categorical variables summarized by numbers and percentages. After Gaussian distribution assessment using Shapiro–Wilk test, continuous variables were reported either by mean and standard deviation or by median, interquartile and ranges when normality was rejected. Contingent on the descriptive analysis, sub-group comparisons were performed for the purpose of hypothesis generation. Categorical variables were compared using either Chi-square test or Fisher-exact test when an expected value in a cell was less than 5. All analyses were performed using R version 3.6.2 and according to sub-groups defined by the intention to use HCCP (ie, the conditions of use of HCCP at the study centre).

**Ethical Considerations**
The study was conducted in accordance with the declaration of Helsinki, Public Health law (Acts No. 2004-806 of 9 August 2004 and 2006-450 of 18 April 2006), the law of modernization of our health system (No. 2016-41 of January 26, 2016), the law on Informatics, files, and Freedoms (No. 78-17 of 6 January 1978 as amended), and general regulations on data Protection 2016/679 of 27 April 2016. The study protocol was approved by the Independent Ethics committee of the University Hospital of Angers, France, on 16-Jan-2019 and registered as n° 2019/5. Patients’ consents were obtained for their inclusion in this study after a letter was sent to all patients alive at time of study initiation.
Table 1 Physician Impression of Change Evaluation

| Analgesic Effect | Definition |
|------------------|------------|
| No effect        | No change  |
| Clinically observable effect but no pain relief | Reduction in pain area OR Decreased intensity of allodynia or hyperalgesia |
| Minimal effect   | 2-point (NRS) or 1-category (VRS) decrease in mean pain intensity AND/OR 2-point (NRS) or 1-category (VRS) decrease in maximum pain intensity |
| Mild effect      | 2-point (NRS) or 1-category (VRS) decrease in mean pain intensity AND 2-point (NRS) or 1-category (VRS) decrease in maximum pain intensity AND Changes in one or more of the following criteria: Decrease in pain flare frequency (but at least 2/day) Decrease in sleep interference score (but at least 1 awake/night) Slight decrease in daily activities interference score Slight decrease in evoked pain reported by the patient 50% decrease in the daily dose of at least one neuropathic pain medication Breakthrough pain analgesic dose reduction or cessation |
| Moderate effect  | 30% to 50% (NRS) or 2-category (VRS) decrease in mean pain intensity: OR 30% to 50% (NRS) or 2-category (VRS) decrease in maximum pain intensity AND Changes in one or more of the following criteria: At least 50% decrease in pain flare frequency No more sleep interference (or rare) At least 50% decrease in daily activities interference score Cessation of at least one neuropathic pain medication OR at least 50% decrease in the daily dose of two neuropathic pain medications |
| Important effect | 30% to 50% (NRS) or 2-category (VRS) decrease in mean pain intensity: OR 30% to 50% (NRS) or 2-category (VRS) decrease in maximum pain intensity AND Changes in two of the following criteria: At least 50% decrease in pain flare frequency No more sleep interference (or rare) At least 50% decrease in daily activities interference score Cessation of at least one neuropathic pain medication OR at least 50% decrease in the daily dose of two neuropathic pain medications |
| Complete effect  | No pain flares (or ≤1/week max) Usual pain: absent No pain interference on sleep (or ≤1/week) No more neuropathic pain medication |

Results
Study Follow-Up
From 01-Jan-2014 to 14-Feb-2020, 993 patients received at least one HCCP application at the ICO Anaesthesiology and Pain department, of which 306 were treated for or following BC (ie, BCSs or BC patients). Among the 306 BCSs/BC
patients, 279 were included in this study. Twenty-six patients were excluded from the study population as they began HCCP treatment before 01-Jan-2014 and one patient was excluded due to missing data. Overall, 1898.7 patches were used, corresponding to 1141 HCCP distinct applications (Figure 1).

**Patients’ Characteristics**

Of the 279 BCSs/BC patients, 277 were women (99.3%) and 2 men (0.7%). Patients were on average 59.2 (SD: 12.4) years old.

Hypertension which was reported by 66 patients (23.7%) was the most frequently reported comorbidity. Overall, 16 patients (5.7%) had bilateral BC (Table 2).

Medical history records indicated that 152/279 patients (54.5%) were taking a previous PNP medication which they stopped before HCCP treatment (Table 2): 55/279 patients (19.7%) had received antiepileptics, 54 (19.4%), antidepressants, and 47 (16.8%), opioids. At the time of the HCCP application, 202 patients (73.2%) concomitantly received at least one analgesic for their PNP (Table 2).

**Pain Characteristics**

Pain was mainly associated with cancer therapy. It was most frequently caused by surgery in 174/279 patients (62.4%). Chemotherapy and radiotherapy were less frequently the cause of pain for 33 patients (11.8%) and 18 patients (6.5%), respectively (Table 2).

More than half of the patients suffered from PNP for more than one year: 107 (38.4%) had their PNP for 1 to 5 years and 38 (13.6%) for more than 5 years (Table 2).

**Characteristics of HCCP Application**

Each patient had received between 1 and 21 HCCP applications, with a median of 3 patches per patient and a mean (SD) of 4.1 (3.5) patches. The median delay between two applications was 67 days (from 1 to 1459 days).

Overall, 190 (68.8%) received HCCP applications as an add-on to a systemic medication for non-controlled neuropathic pain, 77 (27.9%) as monotherapy for neuropathic pain at the discretion of their treating physician, and 9 (3.3%) as add-on to try to stop the systemic medication or reduce it to the minimum effective dose (Table 2).
Table 2 Patients’ and HCCP Treatment Characteristics (N=279)

| Characteristics                          | N (%) or Mean (SD) |
|------------------------------------------|--------------------|
| **Sex**                                  |                    |
| Male                                     | 2 (0.7)            |
| Female                                   | 277 (99.3)         |
| **Age (years)**                          |                    |
| Mean (SD)                                | 59.2 (12.4)        |
| **Comorbidity**                          |                    |
| Hypertension                             | 66 (23.7)          |
| Myocardial infarction                    | 1 (0.4)            |
| Pulmonary embolism                       | 6 (2.2)            |
| Stroke                                   | 3 (1.1)            |
| **Cancer Location**                      |                    |
| Breast - Bilateral                       | 16 (5.7)           |
| Breast - Right                           | 129 (46.2)         |
| Breast - Left                            | 134 (48.0)         |
| **Pain aetiology**                       |                    |
| Pain associated with cancer therapy      |                    |
| Post-surgery chronic pain syndrome       | 174 (62.4)         |
| Chemotherapy induced painful neuropathy  | 33 (11.8)          |
| Radiotherapy induced painful neuropathy  | 18 (6.5)           |
| Non-cancer related pain                  |                    |
| Localized neuropathic pain               | 54 (19.4)          |
| Most painful area of a diffuse neuropathic pain | 20 (7.2) |
| **Duration of PNP before capsaicin use**  |                    |
| <1 year                                  | 115 (41.2)         |
| 1 to 5 years                             | 107 (38.4)         |
| >5 years                                 | 38 (13.6)          |
| **Previous pain medication**             |                    |
| At least 1 previous (stopped before inclusion) | 152 (54.5) |
| At least one antidepressant              | 54 (19.4)          |
| At least one antiepileptic              | 55 (19.7)          |
| At least one opioid                     | 47 (16.8)          |
| At least one other treatment             | 92 (33.0)          |

(Continued)
Patients usually received HCCP applications as second-line treatment (50.5%); however, HCCP applications were used as first-line therapy for 63/279 patients (22.6%) and as third-line or more for 72 patients (25.8%) (Table 2).

HCCP could be applied all over the body according to patient needs. The BCSS/BC patients with pain caused by surgery usually received their HCCP in axillar, breast, and/or dorsal areas, and those under chemotherapy on their hands and feet (Figure 2).

**HCCP Effectiveness**

CGIC was available for 266 patients and 1008 applications. A complete or important analgesic effect was reported at least once by 219/266 patients (82.3%), and a complete effect by 138 patients (51.9%). Out of the 1008 applications, 644 applications (63.9%) and 265 (26.3%) provided complete or important and complete analgesic effect, respectively. Overall, 82/1008 applications (8.1%) resulted in no analgesic effect at all and no effect at all was reported in 16/266 patients (6.0%) (Table 3).

Irrespective of pain aetiology, pain duration, or treatment line, more than half of applications provided complete or important pain analgesic effect (Figures 3 and 4). The proportion of HCCP patch applications providing complete or important PNP analgesic effect was higher in patients with post-surgical PNP (437/684, 63.9%) than in patients with chemotherapy- or radiotherapy-induced PNP (59/112, 52.7% and 45/86, 52.3%, respectively) (Figure 3A). In addition, the earlier the treatment was initiated, the more complete or important the analgesic effect was (Figure 3B). Finally, the proportion of HCCP patch applications providing complete or important PNP analgesic effect varied according to treatment line, the greatest analgesic effect being reported when HCCP was applied as second- or third-line treatment (Figure 4).

Figure 5 presents HCCP effectiveness by patient, pain duration, and first application. After all HCCP applications, the best CGIC response per patient was consistent (from “mild effect” to “complete effect”) in 91.0% of the patients (242/266) and was “minimal effect” to “no effect” in 9.0% of the patients (24/266). Among patients who did not respond to the first application (N=39), 56.4% had at least one additional application (N=22), and 63.6% (N=14) of them experienced important, complete, moderate, or mild analgesic effect with these additional applications.

**Effectiveness in Post-Surgical PNP (PS-PNP) Patients**

CGIC was obtained for 684 applications (174 PS-PNP patients). The highest complete or important effects were observed when the application was performed within 12 months of pain occurrence. Nevertheless, important, or complete effects

**Table 2 (Continued).**

| Characteristics                                      | N (%) or Mean (SD) |
|------------------------------------------------------|--------------------|
| **Ongoing analgesic medication for neuropathic pain** |                    |
| At least 1 ongoing analgesic medication              | 202 (73.2)         |
| **Purpose of the 8% capsaicin patch treatment**       |                    |
| As add-on to a systemic medication for non-controlled pain | 190 (68.8)       |
| As first-line for non-controlled pain                 | 77 (27.9)          |
| As add-on to try to stop the systemic medication or reduce it to the minimum effective dose | 9 (3.3)            |
| **Treatment line for PNP**                           |                    |
| Second-line                                          | 141 (50.5)         |
| First-line                                           | 63 (22.6)          |
| Third-line (or more)                                 | 72 (25.8)          |

**Note:** Patients could have more than one aetiology.

Journal of Pain Research 2022:15
https://doi.org/10.2147/JPR.S341378
Dovepress

Dovepress powered by TCPDF (www.tcpdf.org)
were also observed when pain duration ranged from 1 to 10 years (Table 4). HCCP application as a first-line treatment produced complete or important effect in 59.0% of the cases. This percentage increased for second- and third-line treatments (66.6% and 63.5% of applications with complete or important effect).

The percentage of HCCP applications producing complete or important analgesic response was high and clinically similar in patients with or without concomitant pain medications (65.4% vs 61.1%) or with and without previous pain medications (63.0% vs 61.1), although the distribution of patients with or without concomitant pain medications (p=0.023) or with and without previous pain medications (p=0.003) statistically significantly differed (Table 4).

### Safety Profile of HCCP

HCCP was generally well tolerated. The most common AEs were at application site (ie, local reactions): 152/279 patients (54.4%) reported at least one local reaction following at least one of the HCCP application. These local reactions were mainly burning sensation or pain, which was reported at least once by 128/279 patients (45.9%), followed by erythema (86/279 patients, 30.8%). Frostbite due to cooling as part of the application procedure was observed in 4/279 (1.4%) patients. Other reported local reactions were 3 cases of pruritus, 1 case of plaster allergy, and 1 case of oedema. High

| Area | Number of HCCP applications by area | Number of patients (%) with at least 1 HCCP application per area |
|------|-------------------------------------|---------------------------------------------------------------|
| 1    | 185                                 | 71 (25.4)                                                     |
| 2    | 404                                 | 140 (50.2)                                                    |
| 3    | 472                                 | 151 (54.1)                                                    |
| 5    | 14                                  | 3 (1.1)                                                       |
| 6    | 11                                  | 6 (2.2)                                                       |
| 7    | 36                                  | 20 (7.2)                                                      |
| 8    | 64                                  | 37 (13.3)                                                     |
| 9    | 103                                 | 39 (14.0)                                                     |
| 10   | 84                                  | 34 (12.2)                                                     |
| 11   | 5                                   | 3 (1.1)                                                       |
| 12   | 30                                  | 18 (6.5)                                                      |
| 13   | 57                                  | 19 (6.8)                                                      |
| 14   | 56                                  | 16 (5.7)                                                      |
| 15   | 63                                  | 19 (6.8)                                                      |
| 16   | 125                                 | 36 (12.9)                                                     |
| 17   | 76                                  | 37 (13.3)                                                     |
| 18   | 85                                  | 41 (14.7)                                                     |
| 19   | 93                                  | 38 (13.6)                                                     |
| 20   | 98                                  | 36 (12.9)                                                     |

**Figure 2** Description of HCCP applications by location.  
**Notes**: One patch could be applied on several areas. For example, patches were frequently applied on area #2 and area #1, and/or area #3. Areas #1, #2, #3, and #9 are frequently associated with PS-PNP and areas #16 and #20 with CT-PNP.

**Table 4**

| Area | Number of HCCP applications by area | Number of patients (%) with at least 1 HCCP application per area |
|------|-------------------------------------|---------------------------------------------------------------|
| 1    | 185                                 | 71 (25.4)                                                     |
| 2    | 404                                 | 140 (50.2)                                                    |
| 3    | 472                                 | 151 (54.1)                                                    |
| 5    | 14                                  | 3 (1.1)                                                       |
| 6    | 11                                  | 6 (2.2)                                                       |
| 7    | 36                                  | 20 (7.2)                                                      |
| 8    | 64                                  | 37 (13.3)                                                     |
| 9    | 103                                 | 39 (14.0)                                                     |
| 10   | 84                                  | 34 (12.2)                                                     |
| 11   | 5                                   | 3 (1.1)                                                       |
| 12   | 30                                  | 18 (6.5)                                                      |
| 13   | 57                                  | 19 (6.8)                                                      |
| 14   | 56                                  | 16 (5.7)                                                      |
| 15   | 63                                  | 19 (6.8)                                                      |
| 16   | 125                                 | 36 (12.9)                                                     |
| 17   | 76                                  | 37 (13.3)                                                     |
| 18   | 85                                  | 41 (14.7)                                                     |
| 19   | 93                                  | 38 (13.6)                                                     |
| 20   | 98                                  | 36 (12.9)                                                     |
blood pressure was reported at least once by 20/279 patients (7.2%). Other systemic AEs were rare, they included: 4 cases of headache, 1 case of reflex syncope, and 1 case of nausea.

Procedural pain at application site was rated as very intense during 52/1141 applications (4.6%), intense for 174 applications (15.2%), moderate for 247 applications (21.6%), and mild for 347 applications (30.4%); no information was collected during 321 applications (28.1%). At study centre discharge, pain at application site was rated as very intense for

Table 3 Effect of HCCP Treatment on CGIC Scores by Patient (N=266) or per Application (N=1008)

| Analgesic Effect                        | By Patient (N=266) | Per Application (N=1008) |
|----------------------------------------|-------------------|--------------------------|
| Complete                               | 138 (51.9)        | 265 (26.3)               |
| Important                              | 81 (30.5)         | 379 (37.6)               |
| Moderate                               | 15 (5.6)          | 153 (15.2)               |
| Mild                                   | 8 (3.0)           | 47 (4.7)                 |
| Minimal                                | 8 (3.0)           | 53 (5.3)                 |
| Clinically observable effect without pain relief | 0 (0.0)         | 22 (2.2)                 |
| No effect                              | 16 (6.0)          | 82 (8.1)                 |
| Complete or important effect           | 219 (82.3)        | 644 (63.9)               |

Notes: Analgesic effect was determined by at least one pain specialist who was not the treating physician based on the database including data from the electronic medical file of included patients (1008 applications). When the analgesic effect was quoted according to the CGIC by more than one pain specialist (792 applications), in case of divergence the worst evaluation was the one recorded. For patient evaluation, the analgesic effect was determined by the maximal effect reported after any of the applications when more than one application was performed.

Figure 3 Effect of HCCP application on CGIC score. (A) By PNP aetiology. (B) By PNP duration.
Figure 4: Effect of HCCP application on CGIC scores by treatment line.

Figure 5: CGIC scores by patient, pain duration and from first application.
Table 4: Effect of HCCP Treatment in PS-PNP BCS/BC Patients on CGIC Scores by Pain or Pain Management Characteristics per Application (N=684)

| Characteristics                     | N     | No Effect | Clinical Observable Effect/No Pain Relief | Minimal Effect | Mild Effect | Moderate Effect | Important Effect | Complete Effect | p-value* |
|--------------------------------------|-------|-----------|-------------------------------------------|---------------|------------|---------------|-----------------|---------------|----------|
|                                      |       | n (%)     | n (%)                                     | n (%)         | n (%)      | n (%)         | n (%)           | n (%)         |          |
| **Pain duration**                    |       |           |                                           |               |            |               |                 |               |          |
| 3 to 6 months                        | 126   | 9 (7.1)   | 4 (3.2)                                  | 4 (3.2)       | 2 (1.6)    | 16 (12.7)     | 58 (46.0)       | 33 (26.2)     | 0.0655   |
| 6 to 12 months                       | 103   | 10 (9.7)  | 0 (0.0)                                  | 3 (2.9)       | 3 (2.9)    | 16 (15.5)     | 42 (40.8)       | 29 (28.2)     |          |
| 1 to 2 years                         | 234   | 17 (7.3)  | 3 (1.3)                                  | 12 (5.1)      | 16 (6.8)   | 44 (18.8)     | 83 (35.5)       | 59 (25.2)     |          |
| 3 to 4 years                         | 102   | 6 (5.9)   | 2 (2.0)                                  | 6 (5.9)       | 6 (5.9)    | 16 (15.7)     | 39 (38.2)       | 27 (26.5)     |          |
| 5 to 10 years                        | 62    | 3 (4.8)   | 6 (9.7)                                  | 2 (3.2)       | 7 (11.3)   | 15 (24.2)     | 16 (25.8)       | 13 (21.0)     |          |
| > 10 years                           | 25    | 3 (12.0)  | 0 (0.0)                                  | 2 (8.0)       | 0 (0.0)    | 6 (24.0)      | 9 (36.0)        | 5 (20.0)      |          |
| **Treatment line**                   |       |           |                                           |               |            |               |                 |               |          |
| First-line                           | 200   | 25 (12.5) | 11 (5.5)                                 | 10 (5.0)      | 9 (4.5)    | 27 (13.5)     | 65 (32.5)       | 53 (26.5)     | 0.0315   |
| Second-line                          | 377   | 20 (5.3)  | 5 (1.3)                                  | 14 (3.7)      | 20 (5.3)   | 67 (17.8)     | 149 (39.5)      | 102 (27.1)    |          |
| Third-line                           | 104   | 6 (5.8)   | 1 (1.0)                                  | 5 (4.8)       | 6 (5.8)    | 20 (19.2)     | 39 (37.5)       | 27 (26.0)     |          |
| **Ongoing pain medication**          |       |           |                                           |               |            |               |                 |               |          |
| No                                   | 239   | 26 (10.9) | 11 (4.6)                                 | 8 (3.3)       | 9 (3.8)    | 39 (16.3)     | 86 (36.0)       | 60 (25.1)     | 0.023    |
| Yes                                  | 445   | 25 (5.6)  | 6 (4.6)                                  | 22 (4.9)      | 26 (5.8)   | 75 (16.9)     | 168 (37.8)      | 123 (27.6)    |          |
| **At least one previous pain medication** |       |           |                                           |               |            |               |                 |               |          |
| No                                   | 313   | 32 (10.2) | 10 (3.2)                                 | 18 (5.8)      | 12 (3.8)   | 38 (12.1)     | 111 (35.5)      | 92 (29.4)     | 0.003    |
| Yes                                  | 371   | 19 (5.1)  | 7 (1.9)                                  | 12 (3.2)      | 23 (6.2)   | 76 (20.5)     | 143 (38.5)      | 91 (24.5)     |          |
| **Antidepressants**                  |       |           |                                           |               |            |               |                 |               |          |
| No                                   | 559   | 46 (8.2)  | 13 (2.3)                                 | 27 (4.8)      | 24 (4.3)   | 87 (15.6)     | 215 (38.5)      | 147 (26.3)    | 0.0645   |
| Yes                                  | 125   | 5 (4.0)   | 4 (3.2)                                  | 3 (2.4)       | 11 (8.8)   | 27 (21.6)     | 39 (31.2)       | 36 (28.8)     |          |
| **Antiepileptics**                   |       |           |                                           |               |            |               |                 |               |          |
| No                                   | 567   | 50 (8.8)  | 16 (2.8)                                 | 28 (4.9)      | 28 (4.9)   | 93 (16.4)     | 202 (35.6)      | 150 (26.5)    | 0.01     |
| Yes                                  | 117   | 1 (0.9)   | 1 (0.9)                                  | 2 (1.7)       | 7 (6.0)    | 21 (17.9)     | 52 (44.4)       | 33 (28.2)     |          |
| **Opioids**                          |       |           |                                           |               |            |               |                 |               |          |
| No                                   | 608   | 44 (7.2)  | 17 (2.8)                                 | 26 (4.3)      | 31 (5.1)   | 99 (16.3)     | 223 (36.7)      | 168 (27.6)    | 0.5172   |
| Yes                                  | 76    | 7 (9.2)   | 0 (0.0)                                  | 4 (5.3)       | 4 (5.3)    | 15 (19.7)     | 31 (40.8)       | 15 (19.7)     |          |

Notes: *p<0.05 indicates that the distribution of patients within groups defined by the effect of HCCP treatment statistically significantly differed according to the considered baseline characteristic.
37/1141 applications (3.2%), intense for 151 applications (13.2%), moderate for 134 applications (11.7%), and mild for 174 applications (15.2%); pain was absent for 97 applications (8.5%), and no information was available for 548 applications (48.0%).

**End-of-Treatment and Study Discontinuation**

Data collection was censored on 14-Oct-2020 for 90 patients (32.3%). Other patients had stopped treatment before the end of the study because they had no more pain (N=63, 22.6%), were lost to follow-up (N=39, 14%), died during the study (N=39, 14%), stopped at their request (N=22, 7.9%), or because of other reasons (N=19, 6.8%). Finally, 7 patients stopped treatment due to lack of efficacy (2.5%). The 39 cases of death were all cancer-related; none was associated with HCCP application.

**Discussion**

Persistent pain after BC treatment remains a complex clinical issue that is still poorly understood (Wang et al, 2018). As (i) definitions of pain vary, (ii) assessment tools are inconsistently used, and (iii) methodology differs between studies, prevalence figures vary, and prevention and pain management strategies require further investigation. This chart review study of a large cohort of BCSs and BC patients (n=279) followed at one centre where all patients from the cohort were treated by topical application of HCCP, may contribute to a better understanding of the patient population and the different types of PNP conditions occurring in this population, as well as the effectiveness and safety of the HCCP treatment.

The population in this chart review study is consistent with expectations. Firstly, less than 1% of the patients from the cohort were male, which was consistent with the literature that reports that approximately 1% of BCs are occurring in males. Secondly, in line with the most used intervention for the treatment of BC, the most common cause for the PNP experienced by the BCSs/BC patients from this study was surgery. Several broad classes of drugs for treating BC are currently available and their use is defined based on tumour characteristics and disease extent resulting in a recommendation for systemic chemotherapy, endocrine therapy, or HER2-directed therapy. In case of breast-conserving surgery, radiotherapy is often offered as adjunctive treatment. Not surprisingly, chemotherapy- or radiotherapy-induced PNP were also observed in the cohort, and some patients experienced more than one type of PNP. The distinct cancer treatments can thus lead to the various types of PNP, all reflected in the study population. Thirdly, as the study centre was a pain centre where patients were referred to, it was not a surprise that most BCSs/BC patients had experienced PNP for over a year.

On average, BCSs/BC patients from this study had 4.1 HCCP applications (from 1 to 21 applications). Consistent with literature, HCCP was most often offered as a second-line treatment and as an add-on to systemic medication used for the treatment of PNP.

HCCP applications resulted in considerable effectiveness in approximately 60% of the patients (complete or important response as measured by the CGIC), irrespective of pain aetiology, duration, or treatment line.

Even though HCCP applications more often provided relief in patients with PS-PNP, complete or important analgesic effect was also reported following over 50% of applications in patients with chemotherapy- or radiotherapy-induced PNP. It is important to note that the earlier the treatment was initiated, the greater the relief. This is consistent with other real-world evidence data from a large study in Germany including several PNP indications.

Moreover, even though some patients did not experience sufficient pain relief with the first applications, upon repeated applications, they could experience benefit from the treatment. In other words, setting realistic expectations about treatment goals is important and may facilitate agreement between physician and patient to continue HCCP treatment even if the initial response to HCCP was deemed insufficient. This observation that repeated HCCP applications may enhance treatment benefit was in line with results from a recent post hoc analysis of repeated treatments with HCCP based on data from two large 52-week trials. Results showed that patients who did not experience a 30% decrease in pain scores from baseline after a first application could respond to subsequent applications.
The largest patient group (62.4%) had PNP resulting from surgery. Further analysis of this large patient population showed that, although patients with the shorter duration of pain experienced more relief [an observation consistent with the findings of other studies27], about 50% of HCCP applications provided complete or important effect in patients with PS-PNP diagnosis for 5–10 or >10 years.

Moreover, 59% of HCCP as first-line treatment caused complete or important effect in PS-PNP patients. This information may support the use of HCCPs earlier in the treatment journey even as a first-line treatment option and is in line with current thinking about treatment algorithms for the treatment of focal neuropathic pain.28,29 Consideration of a first-line treatment with HCCP may be of special interest to the often poly-medicated post-surgical patients as systemic exposure to capsaicin is low and use of HCCP does not seem to lead to major drug interactions and systemic side effects often associated with oral pain treatments.30

At the same time, the effectiveness noted in this chart review study when HCCP was used as second- and third-line treatment options suggested that it could also be a useful treatment for patients who need additional treatment options when others have been exhausted. Moreover, it has been described earlier that adding HCCP treatment to existing treatment for PNP may allow for a reduction of that pre-existing treatment.31

This study presents some limitations. Its first limitations are due to its retrospective nature, with mainly a risk of missing data. However, data collection was exhaustive, the cohort was exceptionally large (279 BCSs/BC patients and 1141 HCCP applications), and patient’s electronic medical files were usually thoroughly completed by the treating physicians following each application. In addition, the evaluation of the analgesic effect was performed retrospectively. To compensate for this weakness, most medical records were evaluated by two independent pain specialists each, and in case of disagreement between them, the most unfavorable evaluation was the one reported. In total, eight different pain specialists who were not the treating physicians were involved in the independent evaluation of the medical records to ensure an impartial assessment. Its second limitation is that the study was monocentric with a potential center effect. Although this may be considered a weakness, it may have certain strengths given consistency in diagnosis, therapeutic approach and follow-up of patients. Finally, the study did not allow for thorough evaluation of the impact of previous or concomitant treatments nor of the impact of the size of the painful skin area in HCCP application responses. Prospective and comparative studies are needed to confirm the results of the present study and further evaluate HCCP treatment for this indication.

Acknowledging the limitations, it was the first time that a study evaluated a large cohort of BCSs/BC patients suffering from PNP following interventions for BC (eg, surgery, medical oncological treatments, or radiotherapy). Patient demographics matched those expected from literature and the PNP conditions observed matched expectations. Given that all patients were treated at one study centre with a similar intervention by a team of physicians specialised in pain management, consistency in method of diagnosis, delivery of therapy, and assessment was high. All these elements contribute to the credibility of findings and given the similarity of the findings with data already available in the literature for other PNP conditions, it is likely that the findings from this study may be extrapolated to BCSs/BC patients treated with HCCP at large.

Conclusion
This study shows that HCCP represents an interesting therapeutic option for BCSs/BC patients suffering from PNP due to cancer or its treatment, as it may provide significant or complete relief. It may be a useful first-line treatment option as the best response with HCCP has been observed when used early in the disease. Although best responses with HCCP are noted in patients with PNP following BC surgery, important or complete relief has also been observed in BCSs/BC patients with pain of other aetiology, in those with long-term pain, and as a second- or third-line treatment. Finally, physicians and patients need to understand that it may be useful to reapply HCCP even if initial responses are not fully meeting expectations considering its favourable risk-benefit profile and that continuous improvement is experienced with repeated applications.
Abbreviations
BCSs/BC, breast cancer survivors or breast cancer patients; PNP, peripheral neuropathic pain; HCCP, high-concentration (179 mg) capsaicin patches; CT–PNP, chemotherapy - peripheral neuropathic pain.; PS–PNP, post-surgical peripheral neuropathic pain.; CGIC, Clinical Global Impression of Change; NRS, numeric rating scale; VRS, verbal rating scale; CT, chemotherapy; RT, radiotherapy.

Data Sharing Statement
The data that support the findings of this study are available from D. Dupoiron, the corresponding author, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of D. Dupoiron, the corresponding author.

Ethics Approval and Consent to Participate
The study was conducted in accordance with the declaration of Helsinki; Public Health law (Acts No. 2004-806 of 9 August 2004 and 2006-450 of 18 April 2006), the law of modernization of our health system (No. 2016-41 of January 26, 2016), the law on Informatics, files, and Freedoms (No. 78-17 of 6 January 1978 as amended), and general regulations on data Protection 2016/679 of 27 April 2016. The study protocol was approved by the Independent Ethics committee of the University Hospital of Angers, France, on 16-Jan-2019 and registered as n° 2019/5. Patients’ consents were obtained for their inclusion in this study after a letter was sent to all patients alive at time of study initiation.

Acknowledgments
The authors want to thank Abelia Science (Matthieu Chanard, Fabienne Péretz, and Carolina Rojido) for their help in writing the manuscript.

Author Contributions
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Funding
This study was financially supported by Grünenthal GmbH.

Disclosure
D. Dupoiron, S. Jubier-Hamon, Y. M. Pluchon and T. Delorme received consultant fees from Grünenthal. Dr Nathalie Lebrec reports grants from Institut de Cancérologie de L’Ouest -Angers, during the conduct of the study. The authors declare no other conflicts of interest.

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
2. Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027–e1037. doi:10.1016/S2214-109X(20)30215-1
3. van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ. Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage. 2016;51(6):1070–1090 e9. doi:10.1016/j.jpainsymman.2015.12.340
4. Cancer INd. La vie cinq ans après un diagnostic de Cancer – Rapport; 2018.
5. Gartner R, Jensen MB, Nielsen J, Ewertz M, Kroman N, Kehlet H. Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA. 2009;302(18):1985–1992. doi:10.1001/jama.2009.1568
6. Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Chronic pain and other symptoms among breast cancer survivors: prevalence, predictors, and effects on quality of life. Breast Cancer Res Treat. 2018;167(1):157–169. doi:10.1007/s10549-017-4485-0
7. Ilhan E, Chee E, Hush J, Moloney N. The prevalence of neuropathic pain is high after treatment for breast cancer: a systematic review. Pain. 2017;158(11):2082–2091. doi:10.1097/j.pain.0000000000001004
8. Schou Bredal I, Smeyna NA, Ottesen S, Warncke T, Schlichting E. Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. J Pain Symptom Manage. 2014;48(5):852–862. doi:10.1016/j.jpainsymman.2013.12.239
9. Fontes F, Goncalves M, Pereira S, Lunet N. Neuropathic pain after breast cancer treatment and its impact on sleep quality one year after cancer diagnosis. Breast. 2017;33:125–131. doi:10.1016/j.breast.2017.03.013
10. Leysen L, Adriaenssens N, Nijs J, et al. Chronic pain in breast cancer survivors: nociceptive, neuropathic, or central sensitization pain? Pain Pract. 2019;19(2):183–195. doi:10.1111/papr.12732
11. Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53–59. doi:10.1097/j.pain.0000000000002165
12. Jordan B, Margulies A, Cardoso F, et al. Systemic antitumor therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EOANO clinical practice guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020;31(10):1306–1319. doi:10.1016/j.annonc.2020.07.003
13. Attal N, Bouchassira D. Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? Pain. 2015;156(Suppl 1):S104–S114. doi:10.1097/01.j.pain.0000460358.01998.15
14. Nabholtz JM. Long-term safety of aromatase inhibitors in the treatment of breast cancer. Ther Clin Risk Manag. 2008;4(1):189–204. doi:10.2147/term.s1566
15. Cabezon-Gutierrez L, Custodio-Cabello S, Palka-Kotlowska M, Khosravi-Shahi P. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: a systematic review. J Pain Symptom Manage. 2020;60(5):1047–1054 e1. doi:10.1016/j.jpainsymman.2020.06.026
16. van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787–803 e18. doi:10.1016/j.clinthera.2017.02.010
17. Banerjee S, McCormack S. Capsaicin for Acute or Chronic Non-Cancer Pain: A Review of Clinical Effectiveness, Safety, and Cost-Effectiveness. CADTH Rapid Response Reports; 2020.
18. Andan P, Elsafa E, Privitera R, et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res. 2019;12:2039–2052. doi:10.2147/JPR.S213912
19. Filipczak-Bryniarska I, Krzyzewski RM, Kucharz J, et al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. Med Oncol. 2017;34(9):162. doi:10.1007/s10566-017-0105-1
20. Perrot S, Lanteri-Minet M. Patients’ global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. Eur J Pain. 2019;23(6):1117–1128. doi:10.1002/ejp.1378
21. Studenski S, Hayes RP, Leibowitz RQ, et al. Clinical global impression of change in physical frailty: development of a measure based on clinical judgment. J Am Geriatr Soc. 2004;52(9):1560–1566. doi:10.1111/j.1532-5415.2004.52423.x
22. Gucalp A, Traina TA, Eisner JR, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019;173(1):37–48. doi:10.1007/s10549-018-4921-9
23. McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clinical diagnosis and management of breast cancer. J Nucl Med. 2016;57(Suppl 1):95–168. doi:10.2967/jnumed.115.157834
24. Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105–111. doi:10.1093/bja/act208
25. Maihofner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: impact of pre-existing pain in the QUEPP study. Eur J Pain. 2014;18(5):671–679. doi:10.1002/j.1526-4110.2013.00415.x
26. Freynhagen R, Arigof C, Erezdoks M, Engeling S, Perrot S. Progressive response to repeat application of capsaicin 179 mg (8% w/w) cutaneous patch in peripheral neuropathic pain: comprehensive new analysis and clinical implications. Pain Med. 2021;22(10):2324–2336. doi:10.1093/pmn/pnab113
27. Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673–683. doi:10.1185/03007995.2013.792246
28. Bates D, Schultheis BC, Hanes MC, et al. A comprehensive algorithm for management of neuropathic pain. Pain Med. 2019;20(Suppl Supplement 1):S2–S12. doi:10.1093/pmn/pmz075
29. Huygen F, Kern KU, Perez C. Expert opinion: exploring the effectiveness and tolerability of capsaicin 179 mg cutaneous patch and pregabalin in the treatment of peripheral neuropathic pain. J Pain Res. 2020;13:2585–2597. doi:10.2147/JPR.S263054
30. Bonezzi C, Costantini A, Crusco G, et al. Capsaicin 8% dermal patch in clinical practice: an expert opinion. Expert Opin Pharmacother. 2020;21(11):1377–1387. doi:10.1080/14656566.2020.1759550
31. Wagner T, Roth-Daniek A, Sell A, England J, Kern KU. Capsaicin 8% patch for peripheral neuropathic pain: review of treatment best practice from ‘real-world’ clinical experience. Pain Manag. 2012;2(3):239–250. doi:10.2217/pmt.12.13